HMGA2 expression pattern and TERT mutations in tumors of the vulva

Agostini,Antonio; Panagopoulos,Ioannis; Andersen,Hege Kilen; Johannesen,Lene Elisabeth; Davidson,Ben; Tropé,Claes Göran; Heim,Sverre; Micci,Francesca

doi:10.3892/or.2015.3882

HMGA2 expression pattern and TERT mutations in tumors of the vulva

Authors:
- Antonio Agostini
- Ioannis Panagopoulos
- Hege Kilen Andersen
- Lene Elisabeth Johannesen
- Ben Davidson
- Claes Göran Tropé
- Sverre Heim
- Francesca Micci
View Affiliations

Affiliations: Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway, Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway, Department of Gynecology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
Published online on: March 30, 2015 https://doi.org/10.3892/or.2015.3882
Pages: 2675-2680
Copyright: © Agostini et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant tumors of the vulva account for only 5% of cancers of the female genital tract in the USA. The most frequent cancers of the vulva are squamous cell carcinoma (SCC) and malignant melanoma (MM). Little is known about the genetic aberrations carried by these tumors. We report a detailed study of 25 vulva tumors [22 SCC, 2 MM, 1 atypical squamous cell hyperplasia (AH)] analyzed for expression of the high-mobility group AT-hook family member genes HMGA2 and HMGA1, for mutations in the IDH1, IDH2 and TERT genes, and for methylation of the MGMT promoter. The RT-PCR and immunohistochemistry analyses showed that HMGA2 was expressed in the great majority of analyzed samples (20 out of 24; SCC as well as MM) but not in the normal controls. HMGA1, on the other hand, was expressed in both tumors and normal tissues. Five of the 24 tumors (all SCC) showed the C228T mutation in the TERT promoter. Our results showed that HMGA2 and TERT may be of importance in the genesis and/or the progression of tumors of the vulva.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Teixeira MR, Kristensen GB, Abeler VM and Heim S: Karyotypic findings in tumors of the vulva and vagina. Cancer Genet Cytogenet. 111:87–91. 1999. View Article : Google Scholar : PubMed/NCBI
3	Micci F, Teixeira MR, Scheistrøen M, Abeler VM and Heim S: Cytogenetic characterization of tumors of the vulva and vagina. Genes Chromosomes Cancer. 38:137–148. 2003. View Article : Google Scholar : PubMed/NCBI
4	Micci F, Panagopoulos I, Haugom L, Dahlback HS, Pretorius ME, Davidson B, Abeler VM, Tropé CG, Danielsen HE and Heim S: Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva. Genes Chromosomes Cancer. 52:551–563. 2013. View Article : Google Scholar : PubMed/NCBI
5	Tcheung WJ, Selim MA, Herndon JE, Abernethy AP and Nelson KC: Clinicopathologic study of 85 cases of melanoma of the female genitalia. J Am Acad Dermatol. 67:598–605. 2012. View Article : Google Scholar : PubMed/NCBI
6	Håvik AB, Lind GE, Honne H, Meling TR, Scheie D, Hall KS, van den Berg E, Mertens F, Picci P, Lothe RA, Heim S and Brandal P: Sequencing IDH1/2 glioma mutation hotspots in gliomas and malignant peripheral nerve sheath tumors. Neuro Oncol. 16:320–322. 2014. View Article : Google Scholar :
7	Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, et al: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013. View Article : Google Scholar : PubMed/NCBI
8	Esteller M, Hamilton SR, Burger PC, Baylin SB and Herman JG: Inactivation of the DNA repair gene O⁶-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59:793–797. 1999.PubMed/NCBI
9	Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H and Van de Ven WJ: Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet. 10:436–444. 1995. View Article : Google Scholar : PubMed/NCBI
10	Hetland TE, Holth A, Kaern J, Flørenes VA, Tropé CG and Davidson B: HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases. Virchows Arch. 460:505–513. 2012. View Article : Google Scholar : PubMed/NCBI
11	Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M, et al: High level expression of the HMGI (Y) gene during embryonic development. Oncogene. 13:2439–2446. 1996.PubMed/NCBI
12	Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U and Bullerdiek J: HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol. 149:775–779. 1996.PubMed/NCBI
13	Geurts JM, Schoenmakers EF and Van de Ven WJ: Molecular characterization of a complex chromosomal rearrangement in a pleomorphic salivary gland adenoma involving the 3′-UTR of HMGIC. Cancer Genet Cytogenet. 95:198–205. 1997. View Article : Google Scholar : PubMed/NCBI
14	Mine N, Kurose K, Nagai H, Doi D, Ota Y, Yoneyama K, Konishi H, Araki T and Emi M: Gene fusion involving HMGIC is a frequent aberration in uterine leiomyomas. J Hum Genet. 46:408–412. 2001. View Article : Google Scholar : PubMed/NCBI
15	Kazmierczak B, Meyer-Bolte K, Tran KH, Wöckel W, Breightman I, Rosigkeit J, Bartnitzke S and Bullerdiek J: A high frequency of tumors with rearrangements of genes of the HMGI(Y) family in a series of 191 pulmonary chondroid hamartomas. Genes Chromosomes Cancer. 26:125–133. 1999. View Article : Google Scholar : PubMed/NCBI
16	Nyquist Kb, Panagopoulos I, Thorsen J, Roberto R, Wik HS, Tierens A, Heim S and Micci F: t(12;13)(q14;q31) leading to HMGA2 upregulation in acute myeloid leukaemia. Br J Haematol. 157:769–771. 2012. View Article : Google Scholar : PubMed/NCBI
17	Heidenreich B, Rachakonda PS, Hemminki K and Kumar R: TERT promoter mutations in cancer development. Curr Opin Genet Dev. 24:30–37. 2014. View Article : Google Scholar : PubMed/NCBI
18	Patel KP, Barkoh BA, Chen Z, Ma D, Reddy N, Medeiros LJ and Luthra R: Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using highresolution melting curve analysis. J Mol Diagn. 13:678–686. 2011. View Article : Google Scholar : PubMed/NCBI
19	Wagner K, Damm F, Gohring G, Gorlich K, Heuser M, Schafer I, Ottmann O, Lubbert M, Heit W, Kanz L, et al: Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol. 28:2356–2364. 2010. View Article : Google Scholar : PubMed/NCBI
20	Margison GP and Santibáñez-Koref MF: O⁶-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays. 24:255–266. 2002. View Article : Google Scholar : PubMed/NCBI
21	Håvik AB, Brandal P, Honne H, Dahlback HS, Scheie D, Hektoen M, Meling TR, Helseth E, Heim S, Lothe RA and Lind GE: MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med. 10:362012. View Article : Google Scholar : PubMed/NCBI